- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Vital Images 3D Viewer Receives FDA Clearance
Vital Images Inc. announced the FDA has granted 510(k) clearance for 3D viewing through the VitreaView universal viewer.
Vital Images Inc., a Toshiba Medical Systems Group company, has received FDA 510(k) clearance for 3D viewing through the VitreaView universal viewer, the company announced.
The advanced visualization and analysis company introduced VitreaView in June 2011. The viewer is used as a communication tool for DICOM and non-DICOM medical images through a standardized viewer, so clinicians can access the images through various systems.
“Now with 3D and tablet capabilities available via VitreaView, our customers, particularly referring physicians and clinicians, have more functionality and easier access to the tools they need,” Erkan Akyuz, president and CEO of Vital Images, said in a statement. “Also, with access to images through the EMR as part of the Stage 2 Meaningful Use criteria, VitreaView integrated with a certified EMR enables the ability to meet this objective, with a toolset and infrastructure that also meets the needs of clinical users and IT administrators.”
The Nonexistence of Perfect Balance in Radiology
September 16th 2024In the elusive pursuit of reconciling case volume and having an appropriate number of radiologists, the proverbial windsurfer may fare better than stand-up paddleboarders and daredevil surfers at navigating the waves of the profession.
MRI or Ultrasound for Evaluating Pelvic Endometriosis?: Seven Takeaways from a New Literature Review
September 13th 2024While noting the strength of MRI for complete staging of disease and ultrasound’s ability to provide local disease characterization, the authors of a new literature review suggest the two modalities offer comparable results for diagnosing pelvic endometriosis.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
